Kikuchi–Fujimoto disease following vaccination against COVID-19
Tóm tắt
The purpose of this study is to explore the clinicopathological features of Kikuchi–Fujimoto disease (KFD) following vaccination against coronavirus disease 2019 (COVID-19). One case of KFD following vaccination against COVID-19 was examined clinically, histologically, and immunohistochemically. The patient was a 36-year-old Chinese man who suffered from fever and cervical lymph node swelling following simultaneous administration of the COVID-19 vaccine. The patient was diagnosed with KFD based on the histopathological findings of a lymph node core needle biopsy, and his fever and swelling resolved 2 months later without therapy. Although the exact pathogenesis of the development of KFD following immunization remains unknown, this information should be added to the list of potential triggers or factors associated with the development of KFD.
Tài liệu tham khảo
Kucukardali Y, Solmazgul E, Kunter E et al (2007) Kikuchi-Fujimoto disease: analysis of 244 cases. Clin Rheumatol. 26(1):50–54
Perry AM, Choi SM (2018) Kikuchi-Fujimoto disease: a review. Arch Pathol Lab Med. 142(11):1341–1346
Shenjie Xu, Sun Weilian, Liu Jiamei (2019) Kikuchi-Fujimoto disease: a case report and the evaluation of diagnostic procedures. BMC Oral Health. 19(1):223–227
Bosch X, Guilabert A, Miquel R, Campo E (2004) Enigmatic Kikuchi-Fujimoto disease: a comprehensive review. Am J Clin Pathol. 122(1):141–152
Watanabe Toru, Hashidate Hideki, Hirayama Yutaka, Iinuma Yasushi (2012) Kikuchi-Fujimoto disease following vaccination against human papilloma virus infection and Japanese encephalitis. Eur J Pediatr. 171(9):1409–1411
World Health Organization: Draft landscape and tracker of COVID-19 candidate vaccines. (2021). Accessed May 10th, 2021
Xia S, Duan K, Zhang Y et al (2020) Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 324(10):951–960
Xia S, Zhang Y, Wang Y et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 21(1):39–51
Zhang Y, Zeng G, Pan H et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 21(2):181–192
Ella R, Vadrevu KM, Jogdand H et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 21(5):637–646